专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07727988B2 Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione 失效
标题翻译：氮杂双环[3.1.0]己-3-基}烷基）嘧啶二酮
公开(公告)号：US07727988B2
公开(公告)日：2010-06-01
申请号：US11693756
申请日：2007-03-30
申请人： Barbara Bertani , Giorgio Bonanomi , Anna Maria Capelli , Anna Checchia , Romano Di Fabio , Gabriella Gentile , Fabrizio Micheli , Alessandra Pasquarello , Giovanna Tedesco , Silvia Terreni
发明人： Barbara Bertani , Giorgio Bonanomi , Anna Maria Capelli , Anna Checchia , Romano Di Fabio , Gabriella Gentile , Fabrizio Micheli , Alessandra Pasquarello , Giovanna Tedesco , Silvia Terreni
IPC分类号： C07D401/14 , A61K31/513
CPC分类号： C07D401/14 , C07D403/06 , C07D403/14 , C07D409/14 , C07D413/14
摘要： The present invention relates to novel compounds of formula (I)′ or a salt thereof: wherein G is selected from a group consisting of: phenyl, a 5- or 6-membered monocyclic heteroaryl group, or a 8- to 11-membered heteroaryl bicyclic group; A is a group P1 or a group P2 wherein P1 is and the other groups are define in herein.
摘要翻译：本发明涉及新的式（I）化合物或其盐：其中G选自：苯基，5或6元单环杂芳基或8至11元杂芳基双环基团 A是P1组或P2组，其中P1是本文定义的另一组。

2. 发明申请

US20070249642A1 Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione 失效
标题翻译：氮杂双环[3.1.0]己-3-基}烷基）嘧啶二酮
公开(公告)号：US20070249642A1
公开(公告)日：2007-10-25
申请号：US11693756
申请日：2007-03-30
申请人： Barbara Bertani , Giorgio Bonanomi , Anna Capelli , Anna Checchia , Romano Di Fabio , Gabriella Gentile , Fabrizio Micheli , Alessandra Pasquarello , Giovanna Tedesco , Silvia Terreni
发明人： Barbara Bertani , Giorgio Bonanomi , Anna Capelli , Anna Checchia , Romano Di Fabio , Gabriella Gentile , Fabrizio Micheli , Alessandra Pasquarello , Giovanna Tedesco , Silvia Terreni
IPC分类号： A61K31/513 , C07D403/02
CPC分类号： C07D401/14 , C07D403/06 , C07D403/14 , C07D409/14 , C07D413/14
摘要： The present invention relates to novel compounds of formula (I)′ or a salt thereof: wherein G is selected from a group consisting of: phenyl, a 5- or 6-membered monocyclic heteroaryl group, or a 8- to 11-membered heteroaryl bicyclic group; A is a group P1 or a group P2 wherein P1 is and the other groups are define in herein.
摘要翻译：本发明涉及新的式（I）化合物或其盐：其中G选自：苯基，5或6元单环杂芳基或8至11元杂芳基双环基团 A是P1组或P2组，其中P1是本文定义的另一组。

3. 发明授权

US08263782B2 Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors 有权
公开(公告)号：US08263782B2
公开(公告)日：2012-09-11
申请号：US12639129
申请日：2009-12-16
申请人： Luca Arista , Giorgio Bonanomi , Gabriella Gentile , Dieter Hamprecht , Fabrizio Micheli , Anna Maria Capelli , Federica Damiani , Romano Di Fabio , Luca Tarsi , Giovanna Tedesco , Silvia Terreni
发明人： Luca Arista , Giorgio Bonanomi , Gabriella Gentile , Dieter Hamprecht , Fabrizio Micheli , Anna Maria Capelli , Federica Damiani , Romano Di Fabio , Luca Tarsi , Giovanna Tedesco , Silvia Terreni
IPC分类号： C07D215/38
CPC分类号： C07D495/04 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/08
摘要： The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl, indazolyl; p is an integer ranging from 0 to 5; R1 is independently selected from a group consisting of: halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl; or corresponds to a group R5; R2 is hydrogen or C1-4alkyl; R3 is C1-4alkyl; R4 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl; R5 is a moiety selected from the group consisting of: isoxazolyl, —CH2—N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl, 2-pyrrolidinonyl, and such a group is optionally substituted by one or two substituents selected from: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl; and when R1 is chlorine and p is 1, such R1 is not present in the ortho position with respect to the linking bond to the rest of the molecule; and when R1 corresponds to R5, p is 1; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, e.g. to treat drug dependency or as antipsychotic agents.

4. 发明申请

US20100152195A1 Azabicyclo (3.1.0) Hexane Derivatives Useful As Modulators Of Dopamine D3 Receptors 有权
公开(公告)号：US20100152195A1
公开(公告)日：2010-06-17
申请号：US12639129
申请日：2009-12-16
申请人： Luca Arista , Giorgio Bonanomi , Anna Maria Capelli , Federica Damiani , Romano Di Fabio , Gabriella Gentile , Dieter Hamprecht , Fabrizio Micheli , Luca Tarsi , Giovanna Tedesco , Silvia Terreni
发明人： Luca Arista , Giorgio Bonanomi , Anna Maria Capelli , Federica Damiani , Romano Di Fabio , Gabriella Gentile , Dieter Hamprecht , Fabrizio Micheli , Luca Tarsi , Giovanna Tedesco , Silvia Terreni
IPC分类号： A61K31/501 , C07D403/12 , C07D417/14 , A61K31/428 , A61K31/4196 , A61K31/4439 , C07D401/14 , A61K31/4965
CPC分类号： C07D495/04 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/08
摘要： The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl, indazolyl; p is an integer ranging from 0 to 5; R1 is independently selected from a group consisting of: halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl; or corresponds to a group R5; R2 is hydrogen or C1-4alkyl; R3 is C1-4alkyl; R4 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl; R5 is a moiety selected from the group consisting of: isoxazolyl, —CH2—N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl, 2-pyrrolidinonyl, and such a group is optionally substituted by one or two substituents selected from: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl; and when R1 is chlorine and p is 1, such R1 is not present in the ortho position with respect to the linking bond to the rest of the molecule; and when R1 corresponds to R5, p is 1; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, e.g. to treat drug dependency or as antipsychotic agents.

5. 发明授权

US07855298B2 Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine D3 receptors 有权
标题翻译：可用作多巴胺D3受体调节剂的氮杂双环（3.1.0。）己烷衍生物
公开(公告)号：US07855298B2
公开(公告)日：2010-12-21
申请号：US10598200
申请日：2005-02-21
申请人： Luca Arista , Giorgio Bonanomi , Anna Maria Capelli , Federica Damiani , Romano Di Fabio , Gabriella Gentile , Dieter Hamprecht , Fabrizio Micheli , Luca Tarsi , Giovanna Tedesco , Silvia Terreni
发明人： Luca Arista , Giorgio Bonanomi , Anna Maria Capelli , Federica Damiani , Romano Di Fabio , Gabriella Gentile , Dieter Hamprecht , Fabrizio Micheli , Luca Tarsi , Giovanna Tedesco , Silvia Terreni
IPC分类号： C07D215/38
CPC分类号： C07D495/04 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/08
摘要： The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof: 1. wherein G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl, indazolyl; p is an integer ranging from 0 to 5; R1 is independently selected from a group consisting of: halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl; or corresponds to a group R5; R2 is hydrogen or C1-4alkyl; R3 is C1-4alkyl; R4 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl; R5 is a moiety selected from the group consisting of: isoxazolyl, —CH2—N -pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl, 2 -pyrrolidinonyl, and such a group is optionally substituted by one or two substituents selected from: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl; and when R1 is chlorine and p is 1, such R1 is not present in the ortho position with respect to the linking bond to the rest of the molecule; and when R1 corresponds to R5, p is 1; or a salt thereof which are useful as modulators of dopamine D3 receptors, e.g. to treat drug dependency or as antipsychotic agents.
摘要翻译：本发明涉及新的式（I）化合物或其药学上可接受的盐：1.其中G选自：苯基，吡啶基，苯并噻唑基，吲唑基; p为0〜5的整数。 R 1独立地选自：卤素，羟基，氰基，C 1-4烷基，卤代C 1-4烷基，C 1-4烷氧基，卤代C 1-4烷氧基，C 1-4烷酰基; 或对应于R5组; R2是氢或C1-4烷基; R3是C1-4烷基; R 4是氢或苯基，杂环基，5或6元杂芳族基团或8至11元双环基团，其中任何基团任选被1,2,3或4个取代基取代选自：卤素，氰基，C 1-4烷基，卤代C 1-4烷基，C 1-4烷氧基，C 1-4烷酰基; R5是选自以下的部分：异恶唑基，-CH 2 -N-吡咯基，1,1-二氧化-2-异噻唑烷基，噻吩基，噻唑基，吡啶基，2-吡咯烷基，任选地被一个或多个选自以下的两个取代基：卤素，氰基，C 1-4烷基，卤代C 1-4烷基，C 1-4烷氧基，C 1-4烷酰基; 当R1为氯且p为1时，该R1不存在于与分子的其余部分的连接键的邻位; 当R1对应于R5时，p为1; 或其盐，其可用作多巴胺D3受体的调节剂，例如，治疗药物依赖或作为抗精神病药。

6. 发明申请

US20100160336A1 Azabicyclo (3.1.0) Hexane Derivatives Useful As Modulators Of Dopamine D3 Receptors 有权
标题翻译：可用作多巴胺D3受体调节剂的氮杂双环（3.1.0）己烷衍生物
公开(公告)号：US20100160336A1
公开(公告)日：2010-06-24
申请号：US12639282
申请日：2009-12-16
申请人： Luca Arista , Giorgio Bonanomi , Anna Maria Capelli , Federica Damiani , Romano Di Fabio , Gabriella Gentile , Dieter Hamprecht , Fabrizio Micheli , Luca Tarsi , Giovanna Tedesco , Silvia Terreni
发明人： Luca Arista , Giorgio Bonanomi , Anna Maria Capelli , Federica Damiani , Romano Di Fabio , Gabriella Gentile , Dieter Hamprecht , Fabrizio Micheli , Luca Tarsi , Giovanna Tedesco , Silvia Terreni
IPC分类号： A61K31/50 , C07D403/14
CPC分类号： C07D495/04 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/08
摘要： The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl, indazolyl; p is an integer ranging from 0 to 5; R1 is independently selected from a group consisting of: halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl; or corresponds to a group R5; R2 is hydrogen or C1-4alkyl; R3 is C1-4alkyl; R4 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl; R5 is a moiety selected from the group consisting of: isoxazolyl, —CH2—N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl, 2-pyrrolidinonyl, and such a group is optionally substituted by one or two substituents selected from: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl; and when R1 is chlorine and p is 1, such R1 is not present in the ortho position with respect to the linking bond to the rest of the molecule; and when R1 corresponds to R5, p is 1; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, e.g. to treat drug dependency or as antipsychotic agents.
摘要翻译：本发明涉及新的式（I）化合物或其药学上可接受的盐：其中G选自：苯基，吡啶基，苯并噻唑基，吲唑基; p为0〜5的整数。 R 1独立地选自：卤素，羟基，氰基，C 1-4烷基，卤代C 1-4烷基，C 1-4烷氧基，卤代C 1-4烷氧基，C 1-4烷酰基; 或对应于R5组; R2是氢或C1-4烷基; R3是C1-4烷基; R 4是氢或苯基，杂环基，5或6元杂芳族基团或8至11元双环基团，其中任何基团任选被1,2,3或4个取代基取代选自：卤素，氰基，C 1-4烷基，卤代C 1-4烷基，C 1-4烷氧基，C 1-4烷酰基; R5是选自以下的部分：异恶唑基，-CH 2 -N-吡咯基，1,1-二氧化-2-异噻唑烷基，噻吩基，噻唑基，吡啶基，2-吡咯烷酮基，任选地被一个或多个选自以下的两个取代基：卤素，氰基，C 1-4烷基，卤代C 1-4烷基，C 1-4烷氧基，C 1-4烷酰基; 当R1为氯且p为1时，该R1不存在于与分子的其余部分的连接键的邻位; 当R1对应于R5时，p为1; 它们的制备方法，这些方法中使用的中间体，含有它们的药物组合物及其在治疗中的用途，作为多巴胺D3受体的调节剂。治疗药物依赖或作为抗精神病药。

7. 发明申请

US20070142438A1 Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine d3 receptors 有权
公开(公告)号：US20070142438A1
公开(公告)日：2007-06-21
申请号：US10598200
申请日：2005-02-21
申请人： Luca Arista , Giorgio Bonanomi , Anna Capelli , Federica Damiani , Romano Di Fabio , Gabriella Gentile , Dieter Hamprecht , Fabrizio Micheli , Luca Tarsi , Giovanna Tedesco , Silvia Terreni
发明人： Luca Arista , Giorgio Bonanomi , Anna Capelli , Federica Damiani , Romano Di Fabio , Gabriella Gentile , Dieter Hamprecht , Fabrizio Micheli , Luca Tarsi , Giovanna Tedesco , Silvia Terreni
IPC分类号： A61K31/4439 , A61K31/4196 , A61K31/428 , C07D417/14 , C07D403/14
CPC分类号： C07D495/04 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/08
摘要： The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof: 1. wherein G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl, indazolyl; p is an integer ranging from 0 to 5; R1 is independently selected from a group consisting of: halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, halo1-4alkoxy, C1-4alkanoyl; or corresponds to a group R5; R2 is hydrogen or C1-4alkyl; R3 is C1-4alkyl; R4 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl; R5 is a moiety selected from the group consisting of: isoxazolyl, —CH2—N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl, 2-pyrrolidinonyl, and such a group is optionally substituted by one or two substituents selected from: halogen, cyano, C1-4alkyl, halo1-4alkyl, C1-4alkoxy, C1-4alkanoyl; and when R1 is chlorine and p is 1, such R1 is not present in the ortho position with respect to the linking bond to the rest of the molecule; and when R1 corresponds to R5, p is 1; or a salt thereof which are useful as modulators of dopamine D3 receptors, e.g. to treat drug dependency or as antipsychotic agents.

8. 发明申请

US20100016287A1 COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF" 失效
标题翻译：具有DOPAMINE D3受体的亲和性的化合物及其用途“
公开(公告)号：US20100016287A1
公开(公告)日：2010-01-21
申请号：US11569880
申请日：2005-05-31
申请人： Giorgio Bonanomi , Federica Damiani , Gabriella Gentile , Dieter Wolfgang Hamprecht , Fabrizio Micheli , Luca Tarsi , Giovanna Tedesco , Silvia Terreni
发明人： Giorgio Bonanomi , Federica Damiani , Gabriella Gentile , Dieter Wolfgang Hamprecht , Fabrizio Micheli , Luca Tarsi , Giovanna Tedesco , Silvia Terreni
IPC分类号： A61K31/55 , C07D498/04 , A61P25/00
CPC分类号： C07D513/04 , C07D487/04
摘要： Compounds of formula (I) wherein A is a 5 or 6 membered heteroaromatic ring or a 5 or 6 membered heterocyclic ring, and which are useful for treating mental disorders such as schizophrenia are set out herein.
摘要翻译：本文列出了其中A为5或6元杂芳环或5或6元杂环，可用于治疗精神障碍如精神分裂症的式（I）化合物。

9. 发明申请

US20100035914A1 AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE 审中-公开
公开(公告)号：US20100035914A1
公开(公告)日：2010-02-11
申请号：US12440852
申请日：2007-09-07
申请人： Barbara Bertani , Romano Di Fabio , Fabrizio Micheli , Giovanna Tedesco , Silvia Terreni
发明人： Barbara Bertani , Romano Di Fabio , Fabrizio Micheli , Giovanna Tedesco , Silvia Terreni
IPC分类号： A61K31/435 , C07D221/02 , A61P25/24
CPC分类号： C07D221/04
摘要： The present invention relates to novel compounds of formula (I)′, and pharmaceutically acceptable salts, prodrugs or solvates thereof: wherein R1 is hydrogen or C1-4 alkyl; R2 is a group A, K or W wherein A is K is an α or β naphthyl group, optionally substituted by 1 or 2 groups R18, each of them being the same or different; and W is and wherein G is a 5,6-membered monocyclic heteroaryl group, or a 8- to 11-membered heteroaryl bicyclic group; wherein G may be substituted by (R15)p, which can be the same or different; p is an integer from 0 to 5; R3 is selected from the group consisting of: hydrogen, fluorine, and C1-4 alkyl; or corresponds to a group X or X1; R4 is selected from the group consisting of: hydrogen, fluorine, and C1-4 alkyl; or corresponds to a group X or X1; R5 is hydrogen or C1-4 alkyl; R7 is hydrogen or C1-4 alkyl; or is a group X, X1, X2 or X3; wherein X is X1 is X2 is and X3 is R6 is hydrogen or C1-4 alkyl; or is a group X or X1; R9 is C1-4alkyl; R10 is selected from the group consisting of: hydrogen, halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5; or corresponds to a group R8; R8 is a 5-6 membered heterocycle group, which may be substituted by one or two substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy and C1-4alkanoyl; R11 is selected from the group consisting of: hydrogen, halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5; or corresponds to a group R8; R12 is selected from the group consisting of: hydrogen, halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5; or corresponds to a group R8; R13 is selected from the group consisting of: hydrogen, halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5; or corresponds to a group R8; R14 is selected from the group consisting of: hydrogen, halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5; or corresponds to a group R8; R15 is selected from the group consisting of: halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5; or corresponds to a group R8; R16 is hydrogen, C1-4alkyl, C3-6cycloalkyl or C3-6cycloalkylC1-3alkyl; R17 is hydrogen or C1-4alkyl; R18 is selected from the group consisting of: halogen, cyano, and C1-4alkyl; R19 is haloC1-2alkyl; and n is 1 or 2; with the proviso that: if R2 is A, R3, R4, R5, R6, R7, R10, R11, R13, and R14 are hydrogen, and R12 is fluorine, R1 is C1-4 alkyl; if R2 is A, R3, R4, R5, R6, R7, R10, R11, R13, and R14 are hydrogen, and R1 is methyl, R12 is halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl or SF5; or corresponds to a group R8; and processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as serotonin (5-HT), dopamine (DA) and norepinephrine (NE), re-uptake inhibitors.

10. 发明授权

US07989444B2 Compounds having affinity for dopamine D3 receptor and uses thereof 失效
标题翻译：对多巴胺D3受体具有亲和性的化合物及其用途
公开(公告)号：US07989444B2
公开(公告)日：2011-08-02
申请号：US11569880
申请日：2005-05-31
申请人： Giorgio Bonanomi , Federica Damiani , Gabriella Gentile , Dieter Wolfgang Hamprecht , Fabrizio Micheli , Luca Tarsi , Giovanna Tedesco , Silvia Terreni
发明人： Giorgio Bonanomi , Federica Damiani , Gabriella Gentile , Dieter Wolfgang Hamprecht , Fabrizio Micheli , Luca Tarsi , Giovanna Tedesco , Silvia Terreni
IPC分类号： A61P25/18 , A61K31/55 , C07D487/04 , C07D498/04 , C07D513/04
CPC分类号： C07D513/04 , C07D487/04
摘要： Compounds of formula (I) wherein A is a 5 or 6 membered heteroaromatic ring or a 5 or 6 membered heterocyclic ring, and which are useful for treating mental disorders such as schizophrenia are set out herein.
摘要翻译：本文列出了其中A为5或6元杂芳环或5或6元杂环，可用于治疗精神障碍如精神分裂症的式（I）化合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式